Articles

Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients

University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), CIBERONC, Salamanca
University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), CIBERONC, Salamanca
Institut Català D'Oncologia L'Hospitalet
Hospital Clínico Universitario Virgen De La Arrixaca, Murcia
Institut Josep Carreras and Institut Catala d'Oncologia, Hospital Germans Trias i Pujol, Badalona
Hospital De Cabueñes, Gijón
Department of Hematology, IDIBAPS, Hospital Clinic, Barcelona
Hospital De La Santa Creu i Sant Pau, Barcelona
Department of Hematology, University Hospital of Leon
Hospital Universitario 12 de octubre, Universidad Complutense, CNIO, Madrid
Department of Hematology, University Hospital Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBIS / CISC), Sevilla
Hospital Universitario Virgen De Las Nieves, Granada
Hospital Universitario Puerta de Hierro Majadahonda, Madrid
University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), CIBERONC, Salamanca
Hospital Universitario Central De Asturias, Oviedo
Hospital Clínico Universitario Lozano Blesa, IIS Aragón, Zaragoza
Servicio de Hematología y Oncología Médica. Hospital Universitario Morales Meseguer, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia
Complexo Hospitalario Universitario De Santiago, Santiago de Compostela
Hospital Universitario Madrid Sanchinarro, Madrid
Hospital Universitario De Canarias, Tenerife
Hospital General De Segovia, Segovia
H. Universitario Son Llàtzer, IdIsBa, Mallorca
Department of Hematology, IDIBAPS, Hospital Clinic, Barcelona
Hospital Universitario 12 de octubre, Universidad Complutense, CNIO, Madrid
Clínica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona
Hospital Universitario Marqués De Valdecilla (IDIVAL), Universidad De Cantabria, Santander
University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), CIBERONC, Salamanca
Vol. 108 No. 10 (2023): October, 2023 https://doi.org/10.3324/haematol.2022.282490